# JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Source: https://onco.cc/trials/nct06079983/  
OnCo record `nct06079983` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing JSKN003 in HR-positive / HER2-negative breast cancer, now recruiting.

## Summary

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects is a phase 3 interventional study registered as NCT06079983, led by Jiangsu Alphamab Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects. Planned enrolment is 400 participants (estimated). The study started in 2023-12-01 and primary completion is expected in 2026-04-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06079983
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Sponsor: Jiangsu Alphamab Biopharmaceuticals
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06079983: https://clinicaltrials.gov/study/NCT06079983

## Connected records

- cancers: [HER2-low and HER2-ultralow metastatic breast cancer](https://onco.cc/cancers/her2-low-metastatic-breast-cancer/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [JSKN003](https://onco.cc/drugs/jskn003/)
- companies: [Alphamab Oncology](https://onco.cc/companies/alphamab/)

---
JSON: https://onco.cc/api/v1/entities/nct06079983.json